Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 95Active not recruiting 62Recruiting 54Terminated 51Unknown 20Withdrawn 11Not yet recruiting 3Suspended 2No longer available 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2CNS 1

Conditions

Melanoma 2Lung Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Lymphoma 1Histiocytic Sarcoma 1Head and Neck Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Dendritic Cell Sarcoma, Follicular 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

pembrolizumab 2Propranolol 2talimogene laherparepvec 1sargramostim 1romiplostim 1propranolol CR 1imisopasem manganese 1dabrafenib 1cobimetinib 1aldesleukin 1Vemurafenib 1Vaccines 1Standard of Care 1Specimen Handling 1Practice Guidelines as Topic 1Paclitaxel 1Nivolumab 1Nanoparticles 1Ketones 1Interleukin-2 1Glucose 1Diet Therapy 1CA-4948 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × Melanoma × pembrolizumab × Clear all
NCT03384836 2025-07-02

Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery

Roswell Park Cancer Institute

Phase 1/2 Suspended
47 enrolled
Dermatologic

Melanoma

NCT05669352 2025-04-04

A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases

University of Florida

Phase 1/2 Suspended
29 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡